Intensity Therapeutics (INTS) Cash from Financing Activities (2023 - 2026)
Intensity Therapeutics' (INTS) quarterly Cash from Financing Activities came in at $150000.0 in Q1 2026, down 54.27% YoY from $328000.0 in Q1 2025, and down 97.93% on a QoQ basis from $7.3 million in Q4 2025.
Intensity Therapeutics (INTS) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 4 years of Cash from Financing Activities data on file, last reported at $150000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 54.27% year-over-year to $150000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.4 million (up 470.99% YoY) and the FY2025 annual result came in at $18.6 million, up 540.14% from the prior year.
- Cash from Financing Activities slipped to $150000.0 in Q1 2026, from $7.3 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $20.5 million in Q3 2023 to a low of -$241000.0 in Q2 2023.
- A 4-year average of $3.2 million and a median of $328000.0 in 2025 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities plunged 97.99% — and 2025, when it surged 124666.67%.
- Tracing INTS's Cash from Financing Activities over 4 years: stood at -$13000.0 in 2023, then soared by 19146.15% to $2.5 million in 2024, then jumped by 193.01% to $7.3 million in 2025, then sank by 97.93% to $150000.0 in 2026.
- The last three Cash from Financing Activities figures came in at $150000.0 (Q1 2026), $7.3 million (Q4 2025), and $7.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 36.24 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 27.18 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -273.15 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.65 Mn |
| 10 | Intensity Therapeutics | 13.06 Mn | 13.06 Mn | - | 1.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.62 Mn |
| Jun 30, 2026 | 1.62 Mn |
| Mar 31, 2026 | 150,000.00 |
| Mar 31, 2026 | 150,000.00 |
| Dec 31, 2025 | 7.26 Mn |
| Dec 31, 2025 | 7.26 Mn |
| Sep 30, 2025 | 7.24 Mn |
| Sep 30, 2025 | 7.24 Mn |
| Jun 30, 2025 | 3.74 Mn |
| Jun 30, 2025 | 3.74 Mn |
| Mar 31, 2025 | 328,000.00 |
| Mar 31, 2025 | 328,000.00 |
| Dec 31, 2024 | 2.48 Mn |
| Dec 31, 2024 | 2.48 Mn |
| Sep 30, 2024 | 413,000.00 |
| Sep 30, 2024 | 413,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Mar 31, 2024 | 8,000.00 |
| Mar 31, 2024 | 8,000.00 |